{"id":"linezolid-injectable-product","safety":{"commonSideEffects":[{"rate":"1-3%","effect":"Thrombocytopenia"},{"rate":"0.5-2%","effect":"Anemia"},{"rate":"3-10%","effect":"Nausea"},{"rate":"2-11%","effect":"Diarrhea"},{"rate":"0.5-2%","effect":"Headache"},{"rate":"0.3-2%","effect":"Peripheral neuropathy"},{"rate":"0.3-1%","effect":"Optic neuropathy"}]},"_chembl":{"chemblId":"CHEMBL126","moleculeType":"Small molecule","molecularWeight":"337.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Linezolid is an oxazolidinone antibiotic that binds to the bacterial 23S rRNA component of the 50S ribosomal subunit, blocking the initiation of protein synthesis. This mechanism is bacteriostatic against most organisms but can be bactericidal against certain pathogens. It is effective against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).","oneSentence":"Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:17.886Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Methicillin-resistant Staphylococcus aureus (MRSA) infections"},{"name":"Vancomycin-resistant Enterococcus (VRE) infections"},{"name":"Gram-positive bacterial infections including pneumonia and skin infections"}]},"trialDetails":[{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT07228702","phase":"PHASE1","title":"Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Vancouver Coastal Health","startDate":"2025-11","conditions":"Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection","enrollment":1},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT04545788","phase":"NA","title":"Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2020-08-01","conditions":"Tuberculosis","enrollment":200},{"nctId":"NCT02975570","phase":"PHASE3","title":"Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin","status":"WITHDRAWN","sponsor":"Boston University","startDate":"2017-08","conditions":"Tuberculosis Multi Drug Resistant Active","enrollment":""},{"nctId":"NCT00633152","phase":"PHASE2","title":"Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-02","conditions":"Bacterial Infection","enrollment":150},{"nctId":"NCT00666276","phase":"","title":"Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-02","conditions":"Staphylococcal Infections","enrollment":1004}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Linezolid Injectable Product","genericName":"Linezolid Injectable Product","companyName":"Fundacion Clinic per a la Recerca Biomédica","companyId":"fundacion-clinic-per-a-la-recerca-biom-dica","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Used for Methicillin-resistant Staphylococcus aureus (MRSA) infections, Vancomycin-resistant Enterococcus (VRE) infections, Gram-positive bacterial infections including pneumonia and skin infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}